New Research Links GLP-1 RA Use to Reduced Stroke Risk in Type 2 Diabetes Patients Rushad Patell, MDCredit: BIDMC A recent study published at the 66th American Society of Hematology …
Tag:
dermatology
-
-
Health
Terms of Service Agreements. Researchers awarded Synergy Grant to target tumor vessels and boost immunotherapy
Targeting Tumor Blood Vessels: A New Frontier in Cancer Therapy A groundbreaking project called VASC-IMMUNE, recently awarded a prestigious Synergy Grant by the European Research Council, aims to revolutionize cancer …
-
Henning Bliddal, MD, MSci Credit: The Parker Institute Semaglutide Shows Promise in Reducing Knee Osteoarthritis Pain in Obese Individuals In a groundbreaking study, semaglutide, a medication primarily known for its …
-
New Hope for IgA Nephropathy: Promising Treatment Advancements The landscape of IgA nephropathy (IgAN) management is experiencing a remarkable transformation. Driven by decades of research unraveling the disease’s intricate pathophysiology, …
-
Lean Liver Disease: A Hidden Threat Affecting Millions of Americans New research is shining a light on a concerning trend: lean metabolic dysfunction-associated steatotic liver disease (MASLD) is affecting a …
-
Health
Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024
Semaglutide Shows Promise for Non-Diabetic Chronic Kidney Disease in Landmark SMART Trial Exciting news emerged from Kidney Week 2024 as the landmark SMART trial unveiled promising results for semaglutide (Ozempic/Wegovy) …
-
Semaglutide Shows Promise in Reducing Cardiovascular and All-Cause Mortality in Patients with Type 2 Diabetes and CKD New data from the FLOW trial, presented at the American Society of Nephrology’s …
-
Hiddo Heerspink, PharmD, PhDCredit: George Institute for Global Health Semaglutide Shows Promise in Managing Chronic Kidney Disease Without Diabetes A recent clinical trial suggests semaglutide (Ozempic) may hold significant potential …
-
Health
. Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation
Will Herrington, MA, MBBS, MD, FRCP, FERA Credit: Oxford University Empagliflozin Continues to Protect Kidney Health After Trial Completion New data from the EMPA-KIDNEY trial presented at ASN Kidney Week …
-
Jennifer Yi-Chun-Lai Yee, MD, PhD, MPHCredit: Michigan Medicine Sparsentan Shows Promise for Patients with Genetic Focal Segmental Glomerulosclerosis (gFSGS) A recent analysis of the DUPLEX trial, the largest clinical trial …